Live
- Kajol’s style mantra of the day: Life is short, let my pallu be long
- IPL 2024: Sometimes it works, sometimes it doesn't work, says R Sai Kishore on being held back till 19th over
- Treating politician differently from ordinary criminal will violate Constitution: ED tells SC on CM Kejriwal's plea
- Adverse weather conditions may hit mango crops in UP: Experts
- Cong to snatch reservation from Dalits, says Union Minister Pralhad Joshi
- Congress tied hands of our soldiers, we gave them full freedom to retaliate: PM Modi
- Big B on being honoured with Mangeshkar Award: ‘Abhaar aur mera param saubhagya’
- Fashion Entrepreneur Fund opens up for pre registrations
- ICEA shares blueprint for India to become a global leader in chip value chain
- Meera Deosthale describes marriage as a ‘beautiful union yet huge responsibility’
Dr Reddy’s launches 2 drugs in US mkt
City-based Dr Reddy\'s Laboratories Limited announced on Wednesday that it has launched anti-depressant, Bupropion Hydrochloride Extended Release Tablets, 150 mg and 300 mg, as well as muscle relaxant drug Metaxalone in the US.
Hyderabad: City-based Dr Reddy's Laboratories Limited announced on Wednesday that it has launched anti-depressant, Bupropion Hydrochloride Extended Release Tablets, 150 mg and 300 mg, as well as muscle relaxant drug Metaxalone in the US.
The anti-depressant drug is a generic equivalent version of Wellbutrin XL, a trademark of GlaxoSmithKline LLC. The brand and generic sales of the drug was approximately $754 million for the recent twelve months ending July 2017, according to IMS Health.
It may be recalled that Indian generic companies Cipla and Lupin had launched Wellbutrin's generic version of 150 mg and 300 mg dose tablets in April 2016 and June 2017 respectively. However, the generic version of Welbutrin SR (100 mg, 150 mg and 200 mg) is being sold by Dr Reddy's since September 2016.
Metaxalone, which is used for the treatment of skeletal muscle conditions such as pain and injury, is a generic equivalent version of the Skelaxin brand of King Pharmaceuticals Research and Development, Inc. The brand and generics of this drug had sales of around $129 million during the same period as per IMS Health data.
